TY  - GEN
N2  - Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated genes in AML, and leads to higher relapse rates. Several FLT3 inhibitors have been developed, including gilteritinib. Our lab developed a two-step model of early and late resistance to study the mechanism of resistance and relapse to FLT3 inhibitors. Early resistant AML cells are dependent upon the marrow microenvironment for survival. Over time, intrinsic resistance allows independent growth and results in late resistance, leading to disease relapse.
DO  - 10.6083/8049g5745
DO  - DOI
AB  - Acute Myeloid Leukemia (AML) is an aggressive cancer with poor overall survival due to frequent relapse. FMS-like tyrosine kinase (FLT3) is the most commonly mutated genes in AML, and leads to higher relapse rates. Several FLT3 inhibitors have been developed, including gilteritinib. Our lab developed a two-step model of early and late resistance to study the mechanism of resistance and relapse to FLT3 inhibitors. Early resistant AML cells are dependent upon the marrow microenvironment for survival. Over time, intrinsic resistance allows independent growth and results in late resistance, leading to disease relapse.
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
AD  - Oregon Health and Science University
T1  - The FLT3 F691L gatekeeper mutation promotes clinical resistance to Gilteritinib + Venetoclax in AML
DA  - 2022
AU  - Sharzehi, Setareh
AU  - Joshi, Sunil
AU  - Pittsenbarger, Janet
AU  - Bottomly, Daniel
AU  - McWeeney, Shannon
AU  - Tyner, Jeffrey W.
AU  - Traer, Elie
L1  - https://digitalcollections.ohsu.edu/record/9581/files/Sharzehi-Setareh-OHSU-ResearchWeek-2022.pdf
PB  - Oregon Health and Science University
LA  - eng
PY  - 2022
ID  - 9581
L4  - https://digitalcollections.ohsu.edu/record/9581/files/Sharzehi-Setareh-OHSU-ResearchWeek-2022.pdf
KW  - Leukemia, Myeloid, Acute
KW  - FLT3
KW  - microenvironment
KW  - resistance
KW  - kinase inhibitors
TI  - The FLT3 F691L gatekeeper mutation promotes clinical resistance to Gilteritinib + Venetoclax in AML
Y1  - 2022
L2  - https://digitalcollections.ohsu.edu/record/9581/files/Sharzehi-Setareh-OHSU-ResearchWeek-2022.pdf
LK  - https://digitalcollections.ohsu.edu/record/9581/files/Sharzehi-Setareh-OHSU-ResearchWeek-2022.pdf
UR  - https://digitalcollections.ohsu.edu/record/9581/files/Sharzehi-Setareh-OHSU-ResearchWeek-2022.pdf
ER  -